Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO John Maraganore sold 74,000 shares of the stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $126.86, for a total transaction of $9,387,640.00. Following the completion of the sale, the chief executive officer now owns 223,710 shares of the company’s stock, valued at approximately $28,379,850.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at $127.51 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $35.98 and a 1 year high of $147.63. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The business had revenue of $17.10 million for the quarter, compared to the consensus estimate of $28.15 million. During the same period in the prior year, the business posted ($1.21) earnings per share. Alnylam Pharmaceuticals’s revenue was up 24.8% compared to the same quarter last year. analysts forecast that Alnylam Pharmaceuticals, Inc. will post -5.33 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/19/john-maraganore-sells-74000-shares-of-alnylam-pharmaceuticals-inc-alny-stock.html.
A number of hedge funds have recently added to or reduced their stakes in the business. State of Wisconsin Investment Board increased its holdings in Alnylam Pharmaceuticals by 0.7% in the 2nd quarter. State of Wisconsin Investment Board now owns 15,012 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 100 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Alnylam Pharmaceuticals by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 167 shares during the period. Prudential Financial Inc. increased its holdings in Alnylam Pharmaceuticals by 4.8% in the 2nd quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 200 shares during the period. Utah Retirement Systems increased its holdings in Alnylam Pharmaceuticals by 1.5% in the 2nd quarter. Utah Retirement Systems now owns 13,800 shares of the biopharmaceutical company’s stock valued at $1,100,000 after buying an additional 200 shares during the period. Finally, Alliancebernstein L.P. increased its holdings in Alnylam Pharmaceuticals by 0.8% in the 2nd quarter. Alliancebernstein L.P. now owns 47,873 shares of the biopharmaceutical company’s stock valued at $3,818,000 after buying an additional 398 shares during the period. 92.73% of the stock is currently owned by hedge funds and other institutional investors.
ALNY has been the subject of a number of recent analyst reports. Goldman Sachs Group, Inc. (The) upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the company from $62.00 to $163.00 in a research note on Monday, October 2nd. Jefferies Group LLC set a $102.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 25th. B. Riley cut their price target on shares of Alnylam Pharmaceuticals to $220.00 and set a “buy” rating for the company in a research note on Wednesday, November 8th. Barclays PLC increased their price target on shares of Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the company an “equal weight” rating in a research note on Thursday, August 10th. Finally, BMO Capital Markets restated an “outperform” rating and set a $99.00 target price (down previously from $105.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 6th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and seventeen have issued a buy rating to the stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $121.85.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.